/** blogpostTitle: Polymed Q1 FY27: Growth Accelerates, But Margins Tell Two Stories blogpostSlug: polymed-q1 */

Polymed Q1 FY27: Growth Accelerates, But Margins Tell Two Stories

Poly Medicure Limited (Polymed) entered FY27 with a quarter that showed faster growth at the consolidated level, stronger standalone margins, and early signs of scale-up in newer verticals such as cardiology and orthopedics.

For Q1 FY27, consolidated revenue from operations rose to INR 525.4 crore, up 30.3% year on year. However, the company highlighted that acquisitions contributed INR 72.3 crore in the quarter, bringing organic growth to 12.4% on the consolidated base.

The margin picture split sharply between standalone and consolidated results. Standalone operating EBITDA margin improved to 28.0% (from 26.5%), while consolidated EBITDA margin declined to 24.1% (from 26.7%). Gross margins expanded meaningfully on both bases, but higher operating costs, depreciation, and finance costs weighed on consolidated profitability.

Q1 FY27 financial snapshot: Standalone strength vs consolidated complexity

Standalone operations remain the core earnings engine for the group. Standalone revenue grew 12.3% to INR 431.1 crore. Domestic standalone revenue grew 16.2% to INR 146.0 crore, while international standalone revenue rose 10.1% to INR 281.8 crore.

Standalone gross margin expanded to 71.5% from 68.2%. Management attributed this to a better product mix, price hikes implemented in Q1, and inventory gains. Operating EBITDA grew 18.8% to INR 120.8 crore, even as employee benefit expenses increased 28.5%, driven by a 35% increase in minimum wages in Haryana effective 1 April 2026 and higher headcount.

Consolidated revenue grew 30.3% to INR 525.4 crore, with acquisition-driven step-up particularly visible in international revenue. Consolidated gross margin increased to 73.4% from 68.4%, aided by the margin profile of acquired businesses. But operating EBITDA grew only 17.7% to INR 126.7 crore, and consolidated PAT fell 8.4% to INR 85.3 crore.

Segment performance: diversification is showing up in reported revenue

The consolidated segment table highlighted how Polymed’s revenue mix is shifting. Infusion Therapy remains the largest segment at INR 259.2 crore in Q1 FY27, growing 11.1% year on year. Orthopedics contributed INR 49.2 crore, reflecting the consolidation of Citieffe. Cardiology revenue jumped to INR 28.6 crore from INR 2.9 crore, driven by PendraCare acquisition and scale-up in domestic business.

Renal was the soft spot. Revenue declined 3.8% to INR 43.2 crore. Management attributed the pressure to aggressive pricing from Chinese players in India. The company stated it chose to raise prices to cushion raw material inflation rather than defend volume. Importantly, Polymed disclosed that, based on its application, the government has initiated an anti-dumping investigation on imports of dialyzers from China PR and Malaysia.

Others grew 18.5% to INR 141.9 crore, and export incentive revenue was INR 3.3 crore.

Geography and demand: Europe recovers, RoW hit by Middle East disruption

On the consolidated base, domestic revenue rose 16.2% to INR 146.0 crore. International revenue grew 36.7% to INR 376.1 crore. On an organic basis, international revenue was INR 303.8 crore, up 10.4%.

Europe stood out as the strongest region. Europe revenue rose 43.8% to INR 187.3 crore, and management highlighted that it grew 17.6% organically. The company described Europe as a laggard last year and pointed to onboarding of new customers as the reason for recovery.

Rest of World revenue grew 30.3% reported to INR 188.8 crore, but declined 4.0% organically. The company explicitly linked this to a 32% year-on-year decline in Middle East due to the West Asia crisis. Management said demand remains intact and the order book is strong, but shipments are constrained due to disrupted shipping schedules and lack of containers to Middle East ports.

Strategy and guidance: Polymed 3.0 and the FY27 road map

Polymed positioned FY27 as the start of its Polymed 3.0 phase, with a Vision 2030 to double revenue by FY30 while maintaining strong margins. Management described the company’s trajectory as historically dominated by infusion therapy and now expanding into higher-complexity verticals including cardiology, critical care and orthopedics.

The company reiterated FY27 guidance:

• Consolidated revenue guidance of INR 2,300 to 2,400 crore, including full-year consolidation of PendraCare and Citieffe.
• Standalone revenue guidance of INR 1,900 to 2,000 crore, with domestic expected to grow over 20% and international expected to grow over 15%.
• Standalone EBITDA margin guidance of 25% to 27%.
• Consolidated EBITDA margin guidance of 23% to 25%.
• FY27 capex guidance of INR 200 to 225 crore.

Management also indicated that Q1 standalone margins were above guidance due to price hikes and inventory effects, and implied that gross margin could normalize closer to the historical 68% to 69% range in the near term.

Operationally, the company highlighted leadership strengthening with appointments including a CEO for India and APAC, a CEO for Brazil, and a head for the renal business in India.

What to watch next

Polymed’s Q1 FY27 results show a company with two parallel stories: a stable, high-margin standalone base and a consolidated structure absorbing acquisitions, integration costs, and higher operating intensity.

Key variables to track over the next few quarters remain clear from management commentary. Europe’s recovery needs to sustain. Middle East disruptions need to ease for RoW organic growth to normalize. Renal pricing pressure remains a challenge, and the anti-dumping investigation could become a meaningful catalyst if it results in protective measures.

On the strategic side, the company’s medium-term ambition rests on scaling cardiology and orthopedics with regulatory progress and clinical evidence. Polymed disclosed that the PACIFER DES registry of 2,000 patients had enrolled over 840 patients, with full enrollment targeted by end of FY27, and noted cumulative stent deployments had crossed about 13,000 units as of July 2026.

The quarter also underlined balance sheet optionality, with cash and cash equivalents of INR 854.7 crore as of 30 June 2026, described as reserved for strategic initiatives.

If Polymed can maintain mid-teens organic growth while executing integration and navigating geopolitical logistics, FY27 could become an important base year for the company’s stated FY30 doubling ambition.